Virpax Pharmaceuticals Stock (NASDAQ:VRPX)

Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.